Search

We take a deep dive into key industry trends off the back of Clarivate’s Drugs to Watch 2025 report

In part 2 of our roundtable discussion, thought leaders discuss what Trump could do for drug pricing and whether change is to be feared or embraced.

We speak with Clarivate about their report listing eleven key drugs to watch in 2025.

And getting the right people involved from the start. Here’s why collaboration is key for successful clinical development.

Researchers develop a new platform to improve delivery of oligonucleotide therapies to muscle.

Biden pushed drug pricing reforms, whereas Trump is known for deregulation. What does this mean for pharma?

Radiopharmaceuticals are a promising approach to cancer, but some countries are lagging behind. A collaboration hopes to change that.

Why researchers are excited about the potential of extracellular vesicles from umbilical cord-derived stem cells.

We asked three rare disease drug developers about their work, the challenges facing the field, and what they would do with unlimited funds.

A new study reports targeted CRISPR delivery in retinal and neurological disease models – without viral vectors.